Past, Present, and a Glance into the Future of Multiple Myeloma Treatment

Weam Othman Elbezanti; Kishore B Challagundla; Subash C Jonnalagadda; Tulin Budak-Alpdogan; Manoj K Pandey

doi:10.3390/ph16030415

Past, Present, and a Glance into the Future of Multiple Myeloma Treatment

Pharmaceuticals (Basel). 2023 Mar 8;16(3):415. doi: 10.3390/ph16030415.

Authors

Weam Othman Elbezanti^{1

2}, Kishore B Challagundla³, Subash C Jonnalagadda⁴, Tulin Budak-Alpdogan², Manoj K Pandey¹

Affiliations

¹ Department of Biomedical Sciences, Cooper Medical School of Rowan University, 401S Broadway, Camden, NJ 08103, USA.
² Department of Hematology, MD Anderson Cancer Center at Cooper, Cooper Health System, Camden, NJ 08103, USA.
³ Department of Biochemistry and Molecular Biology, The Fred and Pamela Buffett Cancer Center, The Child Health Research Institute, University of Nebraska Medical Center, Omaha, NE 68198, USA.
⁴ Department of Chemistry and Biochemistry, Rowan University, Glassboro, NJ 08028, USA.

Abstract

Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments.

Keywords: B-cell malignancy; bone marrow microenvironment; drug resistance; immunotherapies; multiple myeloma; proteasome inhibitors.

Publication types

Review

Grants and funding

This research was funded by Camden Research Initiative fund (M.K.P., T.B.-A. and S.C.J.), New Jersey Health Foundation (S.C.J. and M.K.P.), and an inter-department fund from Cooper Medical School of Rowan University, Camden, NJ, USA (M.K.P.).